Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel Deems Non-inferiority Trials For J&J’s Doribax Inferior

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Anti-Infective Drugs Advisory votes 10-3 that a 20 percent non-inferiority margin for the antibiotic is not scientifically justifiable.

You may also be interested in...



J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA

End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.

J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA

End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.

FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date

Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.

Related Content

Topics

UsernamePublicRestriction

Register

PS068088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel